Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities~* Genetically diagnosed Prader-Willi Syndrome~* Received at least one dose of Norditropin® treatment~* Pre-pubertal at start of treatment; assessed by Tanner stage 1, or testicular volume below 4ml (according to Tanner 1976)~Exclusion Criteria:~* Pre-treatment with other Growth Hormone preparation prior to treatment with Norditropin®

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).